# US 2026/0183376 A1 · Delivery of bacteria-derived outer membrane vesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0183376 A1
- Document ID: US20260183376A1
- Status: Published application
- Kind: A1
- Application number: 19/421,676
- Filed: 2025-12-16
- Published: 2026-07-02
- Earliest claimed: 2019-05-15
- Assignees: Quadram Institute Bioscience
- Applicants: Quadram Institute Bioscience
- Inventors: Simon Carding; Regis Stentz
- Web page: https://patentgrep.com/patent/US20260183376A1

## CPC

- A61K 39/0216: {Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/55594: {from bacteria}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A method of treating a gastrointestinal (GI) tract auto-immune disease, crohn's disease or colitis, the method comprising administering to a subject in need thereof a pharmaceutical preparation including a therapeutically effective amount of outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier, wherein said OMVs are native OMVs by the Gram-negative commensal bacteria Bacteroides.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the pharmaceutically acceptable carrier is phosphate buffered saline (PBS).

### Claim 38 (depends on 36)

The method according to claim 36, wherein the pharmaceutical preparation includes at least one pharmaceutically active component.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the pharmaceutically active component is a vaccine agent, antigen and/or pathogen component.

### Claim 40 (depends on 36)

The method according to claim 36, wherein the OMV is an adjuvant.

### Claim 41 (depends on 36)

The method according to claim 36, wherein the OMV is administered at the same time as, before, or after administration of a vaccine or one or more vaccine agents.

### Claim 42 (depends on 36)

The method according to claim 36, wherein the wherein the species of Bacteroides producing the OMVs includes B. acidifaciens, B. caccae, B. coprocola, B. coprosuis, B. eggerthii, B. finegoldii, B. fragilis, B. helcogenes, B. intestinalis, B. massiliensis, B. nordii, B. ovatus, B. stercoris, B. thetaiotaomicron, B. vulgatus, B. plebeius, B. uniformis, B. salyersai, B. pyogenes, B. goldsteinii, B. dorei and B. johnsonii and B. xylanisolvens.

### Claim 43 (depends on 36)

A method according to claim 36, wherein the native OMVs are delivered intranasally.

### Claim 44

A method of treating tumour growth or cancer, the method comprising administering to a subject in need thereof a pharmaceutical preparation including a therapeutically effective amount of outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier, wherein said OMVs are native OMVs by the Gram-negative commensal bacteria Bacteroides.

### Claim 45 (depends on 44)

The method of claim 44, wherein the pharmaceutically acceptable carrier is phosphate buffered saline (PBS).

### Claim 46 (depends on 44)

The method according to claim 44, wherein the pharmaceutical preparation includes at least one pharmaceutically active component.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the pharmaceutically active component is a vaccine agent, antigen and/or pathogen component.

### Claim 48 (depends on 44)

The method according to claim 44, wherein the OMV is an adjuvant.

### Claim 49 (depends on 44)

The method according to claim 44, wherein the tumour growth or cancer is breast cancer tumours.

### Claim 50 (depends on 44)

The method according to claim 44, wherein the optimal dose range of OMVs is between 107 and 109.

### Claim 51

A method of treating typhoid, the method comprising administering to a subject in need thereof a pharmaceutical preparation including a therapeutically effective amount of outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier, wherein said OMVs are native OMVs by the Gram-negative commensal bacteria Bacteroides.

### Claim 52 (depends on 51)

The method of claim 51, wherein the pharmaceutically acceptable carrier is phosphate buffered saline (PBS).

### Claim 53 (depends on 51)

The method according to claim 51, wherein the pharmaceutical preparation includes at least one pharmaceutically active component.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the pharmaceutically active component is a vaccine agent, antigen and/or pathogen component.

### Claim 55 (depends on 51)

The method according to claim 51, wherein the OMV is an adjuvant.
